New PET Imaging Agent Promises Improved Detection of Coronary Artery Disease and Reduced Radiation Exposure for Obese Patients
By MedImaging International staff writers Posted on 26 Apr 2016 |
A global leader in the development of diagnostic imaging agents has presented the results of a first Phase 3 study of a new PET imaging agent at the American College of Cardiology (ACC) Annual Scientific Session, in April 2016, in Chicago.
In the study, the new investigational Positron Emission Tomography (PET) imaging agent was compared to Myocardial Perfusion Imaging (MPI) using Single Photon Emission Computed Tomography (SPECT) to assess Coronary Artery Disease (CAD) in patients with a BMI of 30 or higher. Obesity can lead to an increased risk of stroke, heart disease, high blood pressure, or diabetes.
The flurpiridaz F 18 PET imaging agent was developed by Lantheus Medical Imaging (LMI; North Billerica, MA, USA), a company which develops, manufactures, and commercializes diagnostic imaging agents.
The results of the study showed that flurpiridaz F 18 could improve the detection of coronary artery disease in obese patients, compared to SPECT MPI, while at the same time reducing radiation exposure for the patients.
Cesare Orlandi, MD, CMO, Lantheus Medical Imaging, said, "The Phase 3 data sub- analysis presented at ACC show the advantages of flurpiridaz F 18 PET imaging for coronary artery disease detection in obese patients. Flurpiridaz F 18 PET imaging shows superiority over SPECT in an obese population and provides images with better quality, and less attenuation, which can lead to increased diagnostic certainty by physicians. We believe the improved diagnostic accuracy, utility in stress imaging, reduced radiation exposure and potential for quantification of coronary flow reserve provide great promise for flurpiridaz F 18 to become the diagnostic imaging tool of choice for evaluating coronary artery disease in obese patients.”
Related Links:
Lantheus Medical Imaging
In the study, the new investigational Positron Emission Tomography (PET) imaging agent was compared to Myocardial Perfusion Imaging (MPI) using Single Photon Emission Computed Tomography (SPECT) to assess Coronary Artery Disease (CAD) in patients with a BMI of 30 or higher. Obesity can lead to an increased risk of stroke, heart disease, high blood pressure, or diabetes.
The flurpiridaz F 18 PET imaging agent was developed by Lantheus Medical Imaging (LMI; North Billerica, MA, USA), a company which develops, manufactures, and commercializes diagnostic imaging agents.
The results of the study showed that flurpiridaz F 18 could improve the detection of coronary artery disease in obese patients, compared to SPECT MPI, while at the same time reducing radiation exposure for the patients.
Cesare Orlandi, MD, CMO, Lantheus Medical Imaging, said, "The Phase 3 data sub- analysis presented at ACC show the advantages of flurpiridaz F 18 PET imaging for coronary artery disease detection in obese patients. Flurpiridaz F 18 PET imaging shows superiority over SPECT in an obese population and provides images with better quality, and less attenuation, which can lead to increased diagnostic certainty by physicians. We believe the improved diagnostic accuracy, utility in stress imaging, reduced radiation exposure and potential for quantification of coronary flow reserve provide great promise for flurpiridaz F 18 to become the diagnostic imaging tool of choice for evaluating coronary artery disease in obese patients.”
Related Links:
Lantheus Medical Imaging
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure